Key statistics
On Thursday, Compass Pathways PLC (CMPS:NSQ) closed at 7.40, 47.70% above the 52 week low of 5.01 set on Nov 13, 2023.
52-week range
Open | 7.48 |
---|---|
High | 7.53 |
Low | 7.35 |
Bid | 7.06 |
Offer | 7.38 |
Previous close | 7.30 |
Average volume | 308.56k |
---|---|
Shares outstanding | 68.39m |
Free float | 45.30m |
P/E (TTM) | -- |
Market cap | 499.23m USD |
EPS (TTM) | -2.30 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
- Compass Pathways announces second quarter 2024 financial results and business highlights
- Compass Pathways appoints Lori Englebert as Chief Commercial Officer
- Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
- Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
- Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
- Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
- Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
- Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
- Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
- Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
More ▼